| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
6-Aminoquinoline is a synthetic intermediate used in medicinal chemistry. As a building block, it does not have specific biological receptors as its primary targets. The compound is used in the preparation of diaminopyrimidine derivatives as 5-HT4 receptor agonists. The quinoline scaffold is a privileged structure in medicinal chemistry, found in many bioactive compounds including antimalarials and anticancer agents. The compound's amino group allows for diverse derivatization, including amidation, alkylation, and heterocycle formation. Its primary applications are as a synthetic intermediate and analytical standard.
|
|---|---|
| ln Vitro |
In vitro, 6-aminoquinoline is used as a biochemical reagent and organic compound for biomedical research. It is used in the preparation of diaminopyrimidine derivatives as 5-HT4 receptor agonists. It is used as an internal standard in determining serum nicotine and cotinine by HPLC-fluorometric detection. Cellular assays are typically performed on the final compounds synthesized from this building block. The compound's quinoline scaffold allows for various chemical transformations, making it valuable for drug discovery and analytical chemistry.
|
| ln Vivo |
In vivo data for 6-aminoquinoline is limited, as it is primarily a research reagent and synthetic intermediate. The compound is classified for research use only and is not intended for human or veterinary therapeutic applications. However, 5-HT4 receptor agonists and other pharmaceuticals synthesized using this intermediate have been investigated for their therapeutic potential. The compound's primary value lies in its use as a synthetic intermediate and analytical standard. Specific in vivo data for the parent compound is not available in the public literature.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for 6-aminoquinoline are not typically performed, as it is primarily a synthetic intermediate. The compound is used as a building block in the synthesis of 5-HT4 receptor agonists. A typical assay involves using the compound in chemical reactions to prepare diaminopyrimidine derivatives. The compound is dissolved in organic solvents such as DMSO or ethanol. The resulting products can be evaluated for biological activity. Receptor binding assays for 5-HT4 receptors can be performed on the final synthesized compounds. IC₅₀ or binding affinity values are calculated from dose-response curves.
|
| Cell Assay |
Cellular assays for 6-aminoquinoline derivatives typically evaluate 5-HT4 receptor agonist activity. A standard protocol involves culturing cells expressing 5-HT4 receptors in growth medium at 37°C with 5% CO₂. Cells are treated with synthesized compounds at varying concentrations. Receptor activation is assessed by measuring cAMP accumulation or other downstream signaling readouts. Cell viability is assessed using MTT or similar assays. EC₅₀ values are calculated from dose-response curves. The compound's use as an analytical standard is separate from its cellular applications.
|
| Animal Protocol |
In vivo animal studies for 6-aminoquinoline are not standard, as it is a synthetic intermediate rather than a therapeutic candidate. The compound is classified for research use only and is not intended for human or veterinary applications. Any animal studies would typically be conducted on the final 5-HT4 receptor agonists synthesized using this building block. These studies would evaluate efficacy, pharmacokinetics, and safety in appropriate animal models. The compound's primary value lies in its use as a synthetic intermediate and analytical standard.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for 6-aminoquinoline is limited, as it is primarily a research reagent. The compound has a molecular weight of 144.17 g/mol and a molecular formula of C₉H₈N₂. It is a solid at room temperature with a melting point of 114.0-118.0°C. As an aminoquinoline, it may undergo metabolic conjugation and oxidation. Specific ADME data is not available. The compound is stored in a dry, cool place.
|
| Toxicity/Toxicokinetics |
6-Aminoquinoline is classified for research use only and is not intended for human or veterinary applications. Standard safety precautions include handling with appropriate personal protective equipment (gloves, lab coat, safety goggles) in a well-ventilated area. The compound should be stored in a dry, cool place away from incompatible materials. Acute toxicity data is not readily available in the public literature. As with all research chemicals, appropriate laboratory safety practices should be followed. No specific LD₅₀ values or detailed toxicological profiles are available in the public domain.
|
| Additional Infomation |
6-Aminoquinoline (Quinolin-6-amine, CAS 580-15-4) is a biochemical reagent with the molecular formula C₉H₈N₂. It is used as a synthetic intermediate for 5-HT4 receptor agonists and as an internal standard for nicotine and cotinine analysis by HPLC. The compound is classified as a research-use-only compound not intended for diagnostic or therapeutic purposes. It is available from multiple commercial suppliers in various pack sizes. No clinical trials or approved drug status exist for this compound as it is not a therapeutic agent.
|
| Molecular Formula |
C9H8N2
|
|---|---|
| Molecular Weight |
144.17
|
| Exact Mass |
216.022
|
| CAS # |
580-15-4
|
| PubChem CID |
11373
|
| Appearance |
Solid powder
|
| Boiling Point |
192 °C
|
| Melting Point |
115-119 °C(lit.)
|
| Flash Point |
146°C/0.3mm
|
| LogP |
2.398
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
11
|
| Complexity |
136
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC2=C(C=CC(=C2)N)N=C1
|
| InChi Key |
RJSRSRITMWVIQT-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C9H8N2/c10-8-3-4-9-7(6-8)2-1-5-11-9/h1-6H,10H2
|
| Chemical Name |
quinolin-6-amine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.9363 mL | 34.6813 mL | 69.3626 mL | |
| 5 mM | 1.3873 mL | 6.9363 mL | 13.8725 mL | |
| 10 mM | 0.6936 mL | 3.4681 mL | 6.9363 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.